ABSTRACT
Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C) is a new acute-onset systemic inflammatory disease, which mainly affects children. Latent tuberculosis infection (LTBI) is characterized by the presence of immune sensitization to Mycobacterium tuberculosis (MTB) in the absence of any clinical or radiological evidence of active disease. We present a child with MIS-C related to COVID-19, with latent TB in the bone marrow, and satisfactory response to tocilizumab. It is important to pay attention in the investigation of TB cases in countries with a high prevalence of tuberculosis, especially when opting for immunusuppression.
Subject(s)
COVID-19 Drug Treatment , COVID-19 , Latent Tuberculosis , Antibodies, Monoclonal, Humanized , Bone Marrow , COVID-19/complications , Child , Humans , Latent Tuberculosis/complications , Latent Tuberculosis/diagnosis , Latent Tuberculosis/drug therapy , Male , SARS-CoV-2 , Systemic Inflammatory Response SyndromeABSTRACT
Estudio a lactante menor de 5 meses, de sexo femenino, que ingresa con dificultad respiratoria, rechazo alimentario, fiebre de 24 horas de evolución, con miembros superiores deformes, hiperfonético en área pulmonar, soplo sistólico regurgitativo